摘要
目的比较两种不同剂量尿激酶对急性心肌梗死患者血小板活化的不同影响。方法选取入我院治疗的68例急性心肌梗死患者,随机分成四组,分别以75万、125万、150万、175万单位的尿激酶进行治疗,比较几组患者的血小板活化程度,临床疗效和不良反应发生情况。结果 GMP-140、PAC-1、PLT总体上均与尿激酶的剂量呈负性相关关系;175万单位组的ST段下降≥50%和心电图恢复正常比例显著高于75万单位组和100万单位组,P<0.05;总不良反应发生率亦随剂量的加大而增加,175万单位组高达76.47%。结论采用尿激酶治疗急性心肌梗死125万单位～150万单位剂量临床疗效较佳,不良反应发生率较低,为较适宜剂量。
Objective To compare the different effects of two different doses ofurokinase for acute myocardial infarction in patients with platelet activation. Methods 68 patients with acute myocardial infarction for treatment in our hospital were randomly divided into four groups, respectively, 750 000, 1 250 000, 1 500 000, 1 750 000 units for urokinase therapy. The degree ofplatelet activation, clinical efficacy and adverse events were observed. Results GMP-140, PAC-1, the PLT were with negative correlation relationship with a dose of urokinase. The ST segment depression I〉 50% of 1.75 million units group and ECG normal proportion was significantly higher than the 750 000 units group and 100 million units group, P〈0.05. The total incidence of adverse reactions in tandem increased with the dosage increasing in the 1 750 000 units groups, up to 76.47%. Conclusions The clinical effect for dose ofurokinase in the treatment of acute myocardial infarction of 1.25 million units to 150 million unit dose is better, and it is with a lower incidence of adverse reactions and is more appropriate.
出处
《临床医学工程》
2013年第1期57-58,共2页
Clinical Medicine & Engineering
关键词
急性心肌梗死
尿激酶
血小板活化
Acute myocardial infarction
Urokinase
Platelet activation
